98%
921
2 minutes
20
Background: Endotoxaemia is a significant cause of morbidity and mortality in equids due to perfusion impairment and possible destruction of the glycocalyx.
Objectives: To evaluate our hypothesis that endotoxaemia induces changes in global cardiovascular and haematologic parameters and compromises glycocalyx integrity, evidenced by an early rise in plasma shedding products.
Study Design: In vivo experiments METHODS: In a prospective, randomised, controlled experimental trial, endotoxaemia was induced with E. coli B55:O5 LPS 30 ng kg over 30 min IV in six healthy adult horses ventilated with oxygen supplemented with isoflurane. Standard cardiovascular variables were recorded and calculated, and leucocyte counts, lactate, heparan sulphate and syndecan-1 concentration were determined at baseline (B) before endotoxin and at 0, 30, 60 and 120 min after endotoxin. Data were analysed using mixed models and adjusted by Tukey-Kramer (SAS Enterprise Guide Software 7.1).
Results: After endotoxin (120 min), a significant increase (p ≤ 0.05) in cardiac index (43 ± 9 vs. 80 ± 15 mL kg min, p < 0.01), in oxygen delivery index (8 ± 3 vs. 17 ± 4 mL min kg, p <0.001), in pulse pressure variation (8 ± 3 vs. 17 ± 4, p < 0.01) and in lactate (1.55 ± 0,9 vs. 4.4 ± 0.52 mmol L, p < 0.0001) occurred with a decrease in systemic vascular resistance index (247 ± 87 vs. 83 ± 20 dynes s kg cm, p < 0.001), diastolic arterial blood pressure (69 ± 14 vs. 38 ± 5 mmHg; p < 0.001), and leucocyte counts (5.6 ± 1.3 vs. 1.5 ± 0.3 G l, p < 0.0001). No changes in the glycocalyx degradation products could be found.
Conclusion: Short-term experimental endotoxaemia under isoflurane induced anticipated cardiovascular changes but did not alter glycocalyx shedding products in this study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/vms3.70458 | DOI Listing |
J Clin Invest
September 2025
Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.
Background: Statin therapy lowers the risk of major adverse cardiovascular events (MACE) among people with HIV (PWH). Residual risk pathways contributing to excess MACE beyond low-density lipoprotein cholesterol (LDL-C) are not well understood. Our objective was to evaluate the association of statin responsive and other inflammatory and metabolic pathways to MACE in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
View Article and Find Full Text PDFApoptosis
September 2025
Department of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuang, China.
Cardiovascular diseases (CVDs) are a leading cause of death globally, responsible for 32% of all fatalities. They significantly reduce quality of life and life expectancy, while imposing a substantial economic burden on healthcare systems in different countries. High mobility group box 1 (HMGB1), a location-dependent multifunctional protein, plays a significant role in various cell death pathways associated with CVDs.
View Article and Find Full Text PDFCNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFWien Klin Wochenschr
September 2025
3rd Medical Department with Cardiology and Intensive Care Medicine, Clinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.
Background: Acute heart failure (AHF) significantly contributes to cardiovascular morbidity and mortality, bearing a substantial socioeconomic burden. While the dynamics of chronic heart failure have been extensively explored in global patient cohorts, comprehensive data specific to AHF remain limited.
Methods: This retrospective, single-center, real-world study comprises hospitalized patients with AHF, admitted to a tertiary care hospital in Vienna, Austria, between 1 January 2012 and 31 December 2019.
Minerva Cardiol Angiol
September 2025
Department of Pharmacology, MGM Medical College and Hospital, MGM Institute of Health Sciences, Nerul, Navi Mumbai, India.
Liraglutide is a key therapeutic agent in managing type 2 diabetes mellitus (T2DM), with benefits extending beyond glycemic control to address cardiovascular and renal comorbidities. As T2DM prevalence rises globally, the need for medications that provide comprehensive health benefits becomes increasingly important. Liraglutide, a GLP-1 receptor agonist, has demonstrated effectiveness in reducing cardiovascular events, especially among patients with high cardiovascular risk, such as those with a prior history of myocardial infarction or stroke.
View Article and Find Full Text PDF